Other variables studied, age, sex, duration of CRVO, baseline visual acuity, central subfield thickness, total number of anti-VEGF treatment during the study, longest interval between anti-VEGF treatment during the study, history of cardiovascular disease, history of haematological disease and history of neoplasia at baseline, were all not found to be statistically significant. Here, VEGFA is linked to hematologic disorder.